Holen Sie sich die Stockscreener-App
0.8704
2.40%
0.0204
Schlusskurs vom Vortag:
$0.85
Offen:
$0.8802
24-Stunden-Volumen:
3.83M
Relative Volume:
1.04
Marktkapitalisierung:
$188.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-83.01M
KGV:
-1.8472
EPS:
-0.4712
Netto-Cashflow:
$-64.63M
1W Leistung:
+10.61%
1M Leistung:
+24.65%
6M Leistung:
+13.84%
1J Leistung:
+26.55%
1-Tages-Spanne:
$0.7951
$0.888
1-Wochen-Bereich:
$0.7843
$0.947
52-Wochen-Spanne:
$0.5316
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.8704 | 188.88M | 0 | -83.01M | -64.63M | -0.4712 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
TNYATenaya Therapeutics Inc Options - Finviz
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO - Stock Titan
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Investing News Network
Tenaya Therapeutics appoints Eric Hyllengren as CFO By Investing.com - Investing.com Australia
Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026 - marketscreener.com
Tenaya Therapeutics Appoints New Chief Financial Officer - TipRanks
Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA) - Stock Titan
Tenaya Therapeutics appoints Eric Hyllengren as CFO - Investing.com
Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Moomoo
Price to book forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to sales forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Enterprise value to revenue forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Institutional Confidence - TradingKey
Tenaya Therapeutics Inc (TNYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenaya Therapeutics Inc (TNYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - The Manila Times
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym - StreetInsider
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - Investing News Network
Tenaya to present gene therapy trial data Wednesday By Investing.com - Investing.com South Africa
Tenaya to present gene therapy trial data Wednesday - Investing.com
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya director granted options for 120,000 shares | TNYA Insider Trading - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) awards director 120,000 options at $0.7989 - Stock Titan
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):